Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

What Was Tested

Researchers studied Somatostatin and Lanreotide in the context of pancreatitis (after the acute phase) in this randomized controlled trial publication.

The aim is to stop chemotherapy until progression.

REMINET is an academic randomized, double-blind, placebo-controlled, phase II/III study designed to evaluate lanreotide (LAN) as maintenance treatment after L1 chemotherapy in G1-G2 WDDP NET.

Why It Was Studied

Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Main eligibility criteria: adults pts with a metastatic (synchronous or metachronous) or locally advanced, non-resectable, grade 1 or 2 WDDP NETs and documented control disease after L1 therapy at least 4 weeks prior to randomization.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

As a double-blind Somatostatin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Somatostatin could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Clinical Protocols, Disease-Free Survival, Duodenal Neoplasms, Europe, Neuroendocrine Tumors and Pancreatic Neoplasms.

The authors tagged it with the keywords Clinical trial, Duodenopancreatic neuroendocrine tumours, First line and Maintenance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Lanreotide in people with pancreatitis (after the acute phase).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver), a journal based in Netherlands.

More context: the Somatostatin compound page and the Lanreotide compound page, Pancreatitis (after the acute phase) research.